Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | ESR1 | P03372 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.44 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13512817 | 0.93 | KMT2A (0.43) | SMN1; SMN2LMNACYP1A2CYP2D6CYP2C19 | |
| SCHEMBL10078031 | 0.90 | LMNA (0.44) | SMN1; SMN2TSHRLMNACYP1A2CYP2D6 | |
| SCHEMBL12807612 | 0.88 | TSHR (0.56) | SMN1; SMN2TSHRESR1LMNACYP1A2 | |
| SCHEMBL12370893 | 0.87 | MAPT (0.46) | SMN1; SMN2LMNACYP1A2CYP2D6CYP2C19 | |
| SCHEMBL14539284 | 0.86 | LMNA (0.40) | SMN1; SMN2TSHRLMNACYP1A2CYP2D6 | |
| SCHEMBL13512820 | 0.86 | MAPT (0.45) | SMN1; SMN2LMNACYP1A2CYP2D6CYP2C19 | |
| SCHEMBL22245659 | 0.82 | THRB (0.50) | SMN1; SMN2TSHRESR1LMNACYP1A2 | |
| SCHEMBL8666203 | 0.82 | THRB (0.50) | SMN1; SMN2TSHRESR1LMNACYP1A2 | |
| SCHEMBL17301297 | 0.82 | THRB (0.50) | SMN1; SMN2TSHRESR1LMNACYP1A2 | |
| SCHEMBL14370289 | 0.82 | THRB (0.50) | SMN1; SMN2TSHRESR1LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989576-B2 | Triazine derivative, liquid crystal composition, anisotropic material, and liquid crystal display device using the same | FUJIFILM CORPORATION (JP) | 2011-08-02 | — | — | US | disclosed |
| US-7989576-B2 | Triazine derivative, liquid crystal composition, anisotropic material, and liquid crystal display device using the same | FUJIFILM CORPORATION (JP) | 2011-08-02 | — | — | US | disclosed |
| US-20090018305-A1 | TRIAZINE DERIVATIVE, LIQUID CRYSTAL COMPOSITION, ANISOTROPIC MATERIAL, AND LIQUID CRYSTAL DISPLAY DEVICE USING THE SAME | FUJIFILM CORPORATION (JP) | 2009-01-15 | — | — | US | disclosed |
| US-20090018305-A1 | TRIAZINE DERIVATIVE, LIQUID CRYSTAL COMPOSITION, ANISOTROPIC MATERIAL, AND LIQUID CRYSTAL DISPLAY DEVICE USING THE SAME | FUJIFILM CORPORATION (JP) | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018305-A1 | TRIAZINE DERIVATIVE, LIQUID CRYSTAL COMPOSITION, ANISOTROPIC MATERIAL, AND LIQUID CRYSTAL DISPLAY DEVICE USING THE SAME | H1-0, H1-2, CHRM1 | SMN1; SMN2 3943/4885TSHR 284/4885ESR1 2101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.